BMJ Open Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review

Rebecca Mercieca-Bebber,^{1,2} Michael J Palmer,³ Michael Brundage,³ Melanie Calvert,⁴ Martin R Stockler,^{1,5} Madeleine T King^{1,2}

To cite: Mercieca-Bebber R, Palmer MJ, Brundage M, *et al.* Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review. *BMJ Open* 2016;**6**:e010938. doi:10.1136/bmjopen-2015-010938

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2015-010938>).

Received 22 December 2015
Revised 4 May 2016
Accepted 18 May 2016

CrossMark

For numbered affiliations see end of article.

Correspondence to

Rebecca Mercieca-Bebber;
Rebecca.Mercieca@sydney.edu.au

ABSTRACT

Objectives: Patient-reported outcomes (PROs) provide important information about the impact of treatment from the patients' perspective. However, missing PRO data may compromise the interpretability and value of the findings. We aimed to report: (1) a non-technical summary of problems caused by missing PRO data; and (2) a systematic review by collating strategies to: (A) minimise rates of missing PRO data, and (B) facilitate transparent interpretation and reporting of missing PRO data in clinical research. Our systematic review does not address statistical handling of missing PRO data.

Data sources: MEDLINE and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases (inception to 31 March 2015), and citing articles and reference lists from relevant sources.

Eligibility criteria: English articles providing recommendations for reducing missing PRO data rates, or strategies to facilitate transparent interpretation and reporting of missing PRO data were included.

Methods: 2 reviewers independently screened articles against eligibility criteria. Discrepancies were resolved with the research team. Recommendations were extracted and coded according to framework synthesis.

Results: 117 sources (55% discussion papers, 26% original research) met the eligibility criteria. Design and methodological strategies for reducing rates of missing PRO data included: incorporating PRO-specific information into the protocol; carefully designing PRO assessment schedules and defining termination rules; minimising patient burden; appointing a PRO coordinator; PRO-specific training for staff; ensuring PRO studies are adequately resourced; and continuous quality assurance. Strategies for transparent interpretation and reporting of missing PRO data include utilising auxiliary data to inform analysis; transparently reporting baseline PRO scores, rates and reasons for missing data; and methods for handling missing PRO data.

Conclusions: The instance of missing PRO data and its potential to bias clinical research can be minimised by implementing thoughtful design, rigorous methodology and transparent reporting strategies. All members of the research team have a responsibility in implementing such strategies.

Strengths and limitations of this study

- This systematic review collates practical strategies to minimise the problem of missing patient-reported outcome (PRO) data. Recommendations were retrieved from 117 multidisciplinary sources and potential drawbacks of each recommendation are presented.
- Missing PRO data may be preventable in many cases by implementing rigorous study design and methodological strategies, as described in this review.
- In some clinical research settings, missing PRO data is not avoidable due to deteriorating health status of the participants. Strategies to minimise the potential for bias caused by missing PRO data are described.
- This paper discusses one aspect of PRO data quality: data completeness. Many other factors also contribute to high-quality PRO data, including but not limited to appropriateness of PRO measures, timing of PRO assessment, ensuring patients self-complete and clinical versus statistical significance of findings.
- This review excludes non-English sources. The non-English publications may have been relevant; however, given the repetition of themes found in our 117 included sources we do not believe that these would significantly affect our findings.

Patient-reported outcomes (PROs), including health-related quality of life (HRQOL) and specific symptoms, provide unique information about the effect of disease and treatment on the patient. PRO research evidence is crucial for informed clinical and policy decision-making, and is increasingly being used to inform labelling claims for medical products.^{1–3} The quality and value of PRO evidence is contingent on a number of factors, including: provision of a clear rationale for PRO assessment, the choice of PRO measure, the timing of PRO assessments, and ensuring the responses are the patient's

own. One critical PRO quality assurance issue is missing data, defined as "...values that are not available and that would be meaningful for analysis if they were observed" (ref. 4, p. 1355). Conversely, researchers may measure 'PRO assessment compliance', which refers to the number of completed questionnaires received as a proportion of the number expected, given the study design, and the number of patients still alive and enrolled in the study.^{5 6} Both definitions acknowledge that questionnaires are not expected from patients who have died.⁴⁻⁶

The practical and methodological issues associated with missing PRO data received considerable attention in the literature in the 1990s. An expert workshop on the prevention and analysis of missing PRO data in trials led by international cancer trials groups was held in 1996, with findings published in a dedicated special issue of *Statistics in Medicine*.⁷ Yet problems with missing PRO data persist; high rates of missing PRO data continue to be reported in clinical trials,⁸⁻¹⁰ and PRO compliance rates are sometimes so poor that PRO data are not analysed.¹¹

Persisting PRO compliance problems may reflect the sporadic attention the issue has received in the literature over the past 20 years,⁴ most of which is targeted to statisticians handling missing PRO data during analysis. This is problematic for four reasons: first, content targeted at statisticians may be conceptually and technically inaccessible to non-specialists; second, content addressing statistical handling of missing data does not acknowledge that some missing PRO data is preventable through study design and implementation; third, it promotes an attitude that the problem of missing data is the sole responsibility of the statistician; and fourth, appropriate statistical handling of missing PRO data is often contingent on other research data, and this will require consideration at the trial design stage. The broader research team should understand the issues associated with missing data, and their role in minimising related problems. This team includes individuals involved in study design and planning; recruitment; data collection; quality assurance; and analysing, interpreting or reporting of the results. To the best of our knowledge, there has not been a systematic review targeting the role of the broader research team in maximising PRO compliance rates, and minimising the problem of missing PRO data.

This paper has two aims, and is accordingly structured in two parts:

1. To summarise the problems created by missing PRO data in a format accessible to anyone involved in designing, conducting or analysing clinical research.
2. To systematically review the multidisciplinary literature to identify and collate strategies relevant to the entire research team to:
 - A. Maximise PRO compliance rates through study design and implementation;
 - B. Reduce the potential for biased interpretation caused by missing PRO data through PRO-specific strategies for research design, implementation and reporting.

PART 1: THE PROBLEM OF MISSING PRO DATA—A SUMMARY OF THE ISSUES

Missing PRO data create challenges for data analysis, and can compromise the interpretability and value of PRO findings for three major reasons: first, missed observations reduce study power.¹² Studies with secondary PRO end points are usually sufficiently powered for PRO analyses when the sample size calculation is based on a survival primary end point (eg, progression-free survival) because these typically require larger sample sizes. However, a high proportion of missing PRO data will substantially reduce power and inflate standard error.¹³ This increases the risk of type 2 errors, that is, false-negative findings.

Second, and more problematically, missing data may be related to the measured outcome (ie, HRQOL, pain, etc).¹² For example, non-completers who dropped out of Southwest Oncology Group trials due to death had worse HRQOL at baseline, and at time of drop out than other participants.⁵ In many cases, this type of missing PRO data is unavoidable, yet it cannot be ignored as doing so may lead to biased estimates—the extent of which is impossible to calculate.¹³

Third, the presence of missing data undermines randomisation, and makes intention-to-treat analyses (analysing according to randomised groups) less valid as missing data create a need to make assumptions about the data that are not always verifiable.¹⁴

Difficulties in statistically handling missing PRO data

There are many options for statistically handling missing PRO data. Each method makes assumptions about the missing data mechanism,¹⁵ which is a fairly technical system for classifying missing data according to their probable cause (see [box 1](#)). The challenge is to handle missing data in a way that closest resembles the true, albeit unverifiable, missing data mechanism, since the mechanism often has a greater impact on research results than does the proportion of missing data.¹⁶ To use a simple example—if PRO data are truly missing not at random (MNAR; eg, missing due to declining health), but the analysis method used assumes missing data are missing completely at random (eg, missing due to institution error) by excluding cases with missing data, then the analysed data represents only the better-performing patients. Therefore, in addition to some loss of study power, the findings may falsely indicate that PROs are more favourable than is the true case, thus potentially leading to biased interpretation of change over time within groups, or of between-group differences.¹³ If the missing data appear MNAR, and are handled and interpreted sensibly (within the specific clinical and study context), the risk of introducing bias is reduced. Although statistical approaches are available, it is critical to prevent missing data, where possible, rather than to rely solely on statistical approaches. Prevention, statistical handling, interpretation and transparent reporting of missing PRO data are

Box 1 The missing data mechanism

► Missing completely at random (MCAR)

The probability of missing data is unrelated to past, current and future patient-reported outcome (PRO) scores/health status such as administrative errors.¹⁸ MCAR assumes the participants with missing data are a random sample of the whole sample.¹⁸ Therefore, assuming the study is adequately powered, the results should not be altered too much if the MCAR are ignored in analysis; however, the standard error of the estimates will be inflated.¹⁹ Many examples of MCAR are caused by poor study design and implementation, and are hence 'preventable' sources of missing PRO data.

► Missing at random (MAR)

The probability of missing data depends on observed data or a fixed covariate, but not on the current (missing) or future PRO scores; for example, if a particular cultural group has a high proportion of missing data and patients from this group tend to have poorer PRO scores.¹³ Depending on whether the variable contributing to the likelihood of missing data is 'informative' (related to measured health outcome) or 'ignorable' (unrelated), using a statistical method that ignores MAR may distort the findings, potentially introducing bias.¹⁹ MAR is difficult to ascertain, but methods are available to test for (albeit with some uncertainty^{12 20}) and analyse MAR PRO data.^{12 21}

► Missing not at random (MNAR)

The probability of missing data depends on current and future unobserved scores. PRO scores previously observed are constant but would decline at (or after) drop out, and the process of decline is not observed.¹⁸ Data that meet the MNAR assumption are always 'informative', that is, missing due to the patient's declining health status, but the extent of decline is not known because it is not observed. Few methods are available for unbiased analysis of MNAR.²¹

complementary strategies. It is recommended that statistical handling of missing PRO data be undertaken by a statistician as the methods used are technical. Therefore, statistical handling of missing PRO data is not addressed in our systematic review below. Interested readers are referred to Bell and Fairclough¹⁷ for detailed discussion.

PART 2: A SYSTEMATIC REVIEW OF STRATEGIES TO MAXIMISE PRO COMPLIANCE RATES AND REDUCE THE POTENTIAL FOR BIAS

Part 1 of this paper summarised the problem of missing PRO data for the analysis and interpretation of study results. This motivates part 2 of our paper: a systematic review of strategies for all research team members to assist in minimising the problem of missing PRO data.

Systematic review methods

Search strategy

MEDLINE and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases were systematically searched using a search strategy (see online supplementary appendix A) which combined PRO terms with missing data and compliance terms. These databases

were chosen as they canvassed the disciplines of interest to our review, and because they indexed key papers already known to the authors. The search strategy was developed by first reviewing literature to identify key search terms. We sought advice from three librarians with expertise in systematic reviews to ensure all relevant Medical Subject Headings (MeSH) were addressed, and conducted several pilot searches to capture targeted papers. The MEDLINE search was restricted to English language articles. Reference lists and citations of included papers retrieved in the database search were screened (by title) for additional relevant sources, using the same eligibility criteria.

Eligibility criteria

Papers were included if they provided guidance or recommendations for minimising/preventing missing PRO data in prospective research designs, or for transparent interpretation and reporting of missing PRO data to minimise risk of potential interpretation bias. We excluded non-English articles; conference presentations; research protocols; papers discussing statistical handling of missing PRO data, instrument development, proxy-reporting, patient-reported behaviours (smoking, drug use, etc), non-patient samples and papers reporting general study/trial drop-out rates.

Study selection

Two reviewers (RM-B and MJP) independently screened article titles and abstracts using the eligibility criteria. Screening discrepancies were discussed and settled with two senior authors (MB and MTK). Abstracts that appeared to meet the criteria were obtained in full text and assessed against the same criteria. Our search and study selection process complied with Preferred Reported Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines²² (see online supplementary appendix B).

Extraction and coding of recommendations

Recommendations were extracted, coded and analysed using framework synthesis methodology (RM-B).^{23 24} An a priori framework was used to organise recommendations into three categories (study design and planning, during active study, reporting), then coded according to the specific recommendation (eg, minimise patient burden). These codes were refined and developed during the process, and organised into three code levels on completion. For example, the major category of 'minimise patient burden' was subcategorised into 'assistance to patients', 'questionnaire content', 'length of assessments' and 'validated questionnaires'. Each subcategory was further categorised for specificity; for example, the third-level categories for 'length of assessments' includes 'fewer assessments', 'shorter questionnaire', 'use screening questions', etc. Three reviewers (MTK, MJP, MB) each checked 10% of extractions. Frequencies of each unique recommendation were calculated, and potential

drawbacks of each recommendation were described. Two reviewers (MJP, MTK) checked 100% of the final results tables. Disagreements were discussed as a team to achieve consensus.

RESULTS

One hundred and seventeen articles (listed in online supplementary appendix C) met the inclusion criteria (figure 1). These arose from oncology, palliative care and other disease-specific and non-disease-specific PRO literature (table 1).

Design strategies to minimise the problem of missing PRO data

Recommendations for reducing the problem of missing PRO data through study design are summarised in 12 categories in table 2: *PRO assessment schedule*: a clinically informative and feasible assessment schedule should be defined, with acceptable assessment time windows and stopping rules; *collection of auxiliary or supporting data*: collect information to facilitate unbiased interpretation of PRO data in the presence of missing data, such

as clinician-rated health status, observational or proxy-reported data; *eligibility criteria*: include literacy and language requirements, and the need for a valid baseline PRO assessment; *feasibility issues*: considerations for determining required resources and ensuring the PRO study is feasible; *guidance*: for trial team members to standardise administration and maximise PRO completion rates; *mode of questionnaire administration (MOA)*: MOA should be feasible and acceptable, and impact on PRO completion rates should be considered; *minimise participant burden*: employ strategies to ensure PRO assessment is easy and acceptable to participants; *PRO measure*: PRO measures should be clinically relevant, validated, and acceptable to patients; *PROs part of the trial*: incorporate PROs into all relevant study documents and ensure the team is committed to the PRO study; *quality assurance*: prepare databases, study guidance and procedures with ongoing quality assurance in mind; *sample*: ensure the PRO sample size is representative and sufficient for planned analyses; *team involved in design/protocol development*: involve a multidisciplinary team, including PRO experts, clinicians, nurses, site coordinators, patients and others.

Figure 1 PRISMA flow diagram. PRO, patient-reported outcome.

Table 1 Characteristics of included sources

	N	Per cent
Total	117	100.0
Disease		
Cardiovascular disease	3	2.6
Non-specific	22	18.8
Oncology	65	55.6
Orthopaedics	3	2.6
Pain	2	1.7
Palliative care	6	5.1
Women's health	3	2.6
Other	13	11.1
Publication type		
Discussion/review	64	54.7
Guideline	3	2.6
Meta-analysis	2	1.7
Original research	30	25.6
Systematic review	9	7.7
Text book	6	5.1
Other	3	2.6
Year of publication (range)		
1988–1989	3	2.6
1990–1999	40	34.2
2000–2009	47	40.2
2010–2015	27	23.1

The five most frequently recommended design strategies were: baseline PRO completion as an eligibility criterion (n=28), develop guidance for site staff to standardise the administration of PRO questionnaires (n=27), minimise the length of questionnaires to reduce patient burden (n=18), align PRO assessment time points to clinic visits (n=16) and ensure recruiting sites have sufficient resources to run the PRO study (n=15).

Implementation strategies to minimise the problem of missing PRO data

Recommendations for minimising the problem of missing PRO data while the PRO study is active were coded into seven categories in [table 3](#): *administration procedures*: standardised procedures, particularly for site staff, to maximise PRO compliance; *patient education and engagement*: education about the value of PROs in the study, and engagement through study updates or incentives; *maintaining patient records*: contact details and health status should be kept updated; *quality assurance*: procedures and active communication to monitor compliance and intervene if issues are apparent; *site coordinator*: appoint an individual responsible for PRO assessment at recruiting sites with appropriate organisational and communication skills; *team involved in study implementation*: broader trial team must stay engaged and committed to the PRO study, and work together towards its successful completion; and *staff training*: provide initial and ongoing training about PROs, communication skills, methodology; and formats of such training. The most frequently recommended implementation

strategies were: use a PRO completion cover sheet for standardised recording of reasons for missing PRO data (n=39), appoint a site coordinator responsible for PRO assessments (n=33), send reminders about upcoming PRO assessments to site staff (n=30), ensure site staff check completed PRO questionnaires for missed items while the patient is still in the clinic (n=29) and centrally monitor PRO compliance in real-time (n=27).

Strategies for reporting studies with missing PRO data

Strategies for reporting studies with missing PRO data are presented in [table 4](#). These addressed a need for *clearly reported methodology*, including analysis methods; describing the sample, including baseline scores; defining and providing *compliance rates*; *comparing participants with and without missing PRO data*; providing *reasons for missing data* and discussing the *impact of missing data on generalisability* of findings. The most frequently recommended details to report were: rates of missing PRO data (n=26), reasons/types of missing PRO data (n=15), how missing data were handled for the analysis (n=9), discussion of the potential for bias caused by missing PRO data (n=6), and clinical and demographic characteristics of the sample, including baseline PRO scores (n=5).

DISCUSSION

This paper summarises the problems created by missing PRO data, and highlights the need for all members of the research team to assist in minimising the problem of missing data. Our systematic review identified and synthesised a range of practical strategies for all research team members to maximise PRO compliance and reduce the problem of missing PRO data through design, implementation and reporting. These strategies highlight the need for thoughtful planning and incorporation of PROs into all research documents.^{25–30} PRO study design should balance the need for sufficient PRO data with the capacity of patients to self-report, and the feasibility and practicality of site staff to collect it at informative time points.^{31–33} Previous research has demonstrated that involving experienced data collection personnel in PRO study development is crucial to achieving high compliance rates.^{25 34} Strategies for minimising bias caused by missing PRO data involve utilising auxiliary data to inform valid analysis according to the likely missing data mechanism; this must be planned for during study design.

While the PRO study is active, high-level support of the sponsor and advocacy by the PRO expert on the research steering committee (or similar) is essential to emphasise the importance of PRO data. Given the time-sensitive nature of PRO data, quality assurance strategies are crucial to maintaining high standards, particularly real-time monitoring of PRO completion rates to enable timely intervention if compliance falls below prespecified thresholds.³⁵ Land *et al*²⁵ found that targeted

Table 2 Study design and planning strategies to minimise the problem of missing PRO data

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Assessment schedule	Specify PRO assessment time points	Specify the required PRO assessment time points	2	None	Bernhard, Gusset (1998), Beitz (1996)
		Specify the minimum PRO data requirements (eg, 'baseline, on and off treatment, and and/or end of study' (ref. 5, p. 524)	3	May create impression that additional PRO assessments are not important	Bernhard, Cella (1998)
		PRO assessment schedule if treatment schedule is disrupted (ie, will the PRO assessment schedule be altered if the treatment schedule is altered?)	1	None	Fairclough (2010)
	Time point selection (guidance on how to select PRO assessment time points)	Align PRO assessments to clinic visits so that data may be captured while the patient visits the clinic	16	Clinic visits may not be most informative to capture particular treatment effects (eg, chemotherapy toxicity) May be burdensome to participants to attend clinic for regular assessments	Bernhard, Cella (1998), Moinpour (1998), Movsas (2003), Aaronson (1990), Land (2007), Walker (2003), Calvert (2004), Sprague (2003), Revicki (2005), Fairclough (2010), Kyte (2013), Blazeby (2003), Simes (1998)
		Align assessment schedule to a fixed reference point (for ease of calculating when PRO assessments are due)	1	May be burdensome to participants to attend regular assessments	Bernhard, Cella (1998)
		Allow sufficient breaks between PRO assessments	1	May not be feasible if investigators wish to capture acute disease/ treatment effects or their frequency via PROs	Sherman (2005)
		Assess PROs of palliative care patients weekly	4	Does not consider when PRO assessment would be most meaningful	Tang (2002)
		Balance the number of required PRO assessments (not too few, not too many)	4	None	Revicki (2005), Fairclough (2010)
		Consider patient treatment and expected survival when	3	None	Kaasa (2002), Hahn (1998), Atherton (2006)

Continued

Table 2 Continued

Category						Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks		
		planning assessment schedule (added note: avoid PRO assessments beyond the point of expected median survival)				
		Select clinically meaningful time points (ie, ensure that PRO assessments will be taken at clinically informative times, ie, to capture the trajectory of treatment and recovery)	4	Clinically meaningful PRO assessment time points may not align with clinic visits, which may require alternative modes of administration		Ganz (2007), Jordhoy (1999), Tang (2002)
		Event-driven PRO assessment for a subsample (ie, rather than subjecting entire sample to detailed PRO assessments if they experience certain clinical events, it may minimise staff effort and resources to restrict these additional assessments to a subsample only)	2	Event-driven PRO assessment can be logistically challenging to implement		Bernhard, Cella (1998), Simes (1998)
		Focus on short-term outcomes in patients with advanced disease (focusing on long-term outcomes in such samples will lead to high rates of missing PRO data, and uninformative data)	1	May not be clinically meaningful to assess short-term outcomes in all studies		Ganz (2007)
		Justify chosen PRO assessment time points	1	None		Ganz (2007)
		Minimise PRO assessment time points (select fewer time points to minimise burden and resource usage)	3	May sacrifice important information by omitting time points, for example, differences between treatment arms ⁵		Bernhard, Cella (1998), Macefield (2013), Cella (1995)
		Shorter follow-up duration (avoid following up patients for	1	May sacrifice important information by ceasing		Little, Cohen (2012)

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		a longer period of time as participants are more likely to drop out over time)		PRO assessment too early in some studies. Some studies may be interested in long-term follow-up/survival outcomes.	
	Treatment failure/cessation	Continue PRO assessments after treatment failure	6	May be difficult to engage or contact participants beyond point of treatment failure	Hao (2010), Little, D'Agostino (2012), Sprangers (2002), Chassany (2002), Cella (1995), Cella (1994)
		Specify procedures for contacting participants after treatment cessation	3	None	Cella (1994), Revicki, Hao (2010)
		Specify the PRO assessment stopping rule (ie, under what circumstances should PRO assessments discontinue)	3	None	Bell (2014), Kaasa (1992), Young, de Haes (1999)
	Time windows	Define PRO assessment time windows (ie, baseline assessment time window should always end before the intervention/treatment commences. Follow-up assessment time windows should border the period in which treatment effects of interest are anticipated, for example, if the time point is 1 week postsurgery, a valid assessment may occur anytime between 4 and 12 days postsurgery).	12	None	Bernhard, Cella (1998), Cella (1994), Wisniewski (2006), Blazeby (2003), Hopwood (1996), Bernhard, Peterson (1998), Fayers (1997), Hopwood (1998), Revicki (2005), Fairclough (2010), Cella (1995)
		Flexible/large time windows (very narrow time windows may be logistically infeasible to implement and so risk of missing PRO data may be reduced by setting larger time windows)	3	Not all time windows can be flexible, particularly when assessing acute effects of treatment	Bernhard, Cella (1998), Little, Cohen (2012), McMillan (2003)

Continued

Table 2 Continued

Category					Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	
Collect additional/ supporting data (which can be used during PRO data analysis and interpretation)	Auxiliary data (to assist interpretation if there are some missing PRO data). Suggestions of types of auxiliary data in the next column	Additional information about non-responders (type of additional information unspecified)	1	Requires prespecification, and additional time and resources to collect	Kim (2004)
		Clinical data	1	Requires additional time and resources to collect	Newgard (2010)
		Health status (clinician-rated quality of life index, Karnofsky or ECOG performance status)	6	Requires additional clinician time	Coates (1998), Bell (2014), Bernhard, Cella (1998), Simes (1998), Revicki (2005), Fairclough (2010)
		Comorbidity data	1	Requires additional time and resources to collect	Bernhard, Cella (1998)
		Concomitant medications	1	Requires additional time and resources to collect	Beitz (1996)
		Observation data	1	Requires additional time and resources to collect	Kaasa (2002)
		Participant clinical data	1	None	Newgard (2010)
		Participant demographics	2	None	Altman (2007), Newgard (2010)
		Proxy† reports when participant is no longer able to self-complete	21	Proxy reports are not always concordant with participant self-reports. Care must be taken when interpreting proxy data. This is a specialist subject and additional reading is recommended for investigators considering to use proxy assessment. ⁶⁴	Bernhard, Cella (1998), Chassany (2002), Fayers (1997), Jordhoy (2010), Kleinpell-Nowell (2000), Kyte (2013), Machin (1998), Moynihan (1998), Peruselli (1997), Revicki (2005), Rock (2007), Simes (1998), Sprangers (2002), Stewart (1992), Taphoom (2010), Walker (2003)
		Toxicity data	2	Requires additional time and resources to collect, if not already being collected as part of the study	Fairclough (2010), Revicki (2005)

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Eligibility criteria for PRO study (suggestions of specific eligibility or inclusion criteria)	Consider the participants' ability to complete PROs	Unspecified (use an alternative to PRO in final weeks of life)	1	Requires additional time and resources to collect. Additional drawbacks may be apparent depending on specific alternative measure/s used.	Jordhoy (2010)
		Collect reasons for missing PRO data	–	–	See 'cover sheet' section in administration procedures in table 3
		Include—'participant must be able to complete PROs' as an inclusion criterion	2	Ability to complete PRO assessments may change over the course of treatment. Results may not be generalisable to all patients.	Bernhard, Cella (1998), Huntington (2005)
		Exclude patients with language/cognitive barriers from the PRO study only (ie, these participants are able to take part in other aspects of the trial, but will not be included in the PRO study)	2	May reduce the sample size/power of PRO study. Results may not be generalisable to all patients.	Hopwood (1998), Sprague (2003)
	Baseline PRO completion (some sources recommended include baseline PRO completion as an eligibility criterion)		29	None	Bernhard, Cella (1998), Bernhard, Peterson (1998), Calvert (2004), Cella (1994), Cella (1995), Chassany (2002), Conroy (2003), Fayers (1997), Hayden (1993), Hopwood (1998), Hurry (1992), Kaasa (1998), Movsas (2003), Osoba (1992), Osoba (2007), Sadura (1992), Simes (1998), Sprangers (2002), Walker (2003), Young, Maher (1999), Young de Haes (1999) Chassany (2002)
	Include patients with minimal level of impairment (as per baseline PRO) to ensure inclusion of patients with severe disease		1	May lead to selection bias May impact generalisability of results	

Continued

Table 2 Continued

Category					Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	
Feasibility issues of PRO studies	Surviving long enough to complete PROs (palliative care)		3	Difficult to estimate in some cases, so prognostic cues predictive of death may be more practical; may introduce selection bias.	Bakitas (2009), Jordhoy (1999), Chassany (2002)
	Participants' willingness to complete PROs		3	May result in selection bias; patients more willing to take part in PRO study may differ systematically from non-participants.	Fayers (1997), Sprague (2003)
	Pilot study	Determine feasibility of PRO study (potential issues, resources required and/or sample size), and acceptability by conducting a pilot study	9	Requires time and resources	Cella (1994), Cella (1995), Groenvold (1999), Hurny (1992), Moinpour (1989), Kleinpell-Nowell (2000), Young, de Haes (1999), Sherman (2005), Wisniewski (2006)
		Determine compliance targets by conducting a pilot study	1	Requires a long pilot study to determine; significant time and resources	Hahn (1998)
		Conduct a pilot study to determine average time to complete PRO measures	1	Requires time and resources	Kleinpell-Nowell (2000)
		Use the PRO pilot study as a training opportunity for less experienced staff	1	Requires time and resources	Cella (1995)
	PRO resources	Ensure there is sufficient funding for the PRO study and that the PRO study is included in study budget	5	Funding can be difficult to obtain; however, it is possible to minimise costs of PRO studies at no cost to high-quality PRO research	Bernhard, Cella (1998), Cella (1995), Coates (1998), Gotay (2005), Moynihan (1998)
		Resource allocation—ensure recruiting sites are sufficiently resourced for the PRO study	15	Funding can be difficult to obtain across all sites especially if recruiting internationally or trans-nationally.	Bernhard, Cella (1998), Bernhard, Peterson (1998), Hayden (1993), Hopwood (1998), Hopwood (1996), Kaasa (1992), Moinpour

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
	Selection of recruiting sites	Ensure adequate staff at potential sites	2	Funding to employ new staff can be difficult to obtain	(1998), Moynihan (1998), Revicki (2005), Scott (2004), Sprague (2003), Walker (2003), Wisniewski (2006), Young, de Haes (1999) Revicki (2005), Scott (2004)
		Minimise resources required for the PRO study	4	Care must be taken not to sacrifice quality of data or performance	Bernhard, Cella (1998), McMillan (2003)
		Select sites with good compliance record	1	May limit the number of participants recruited; may overly burden particular sites; potential for selection bias ⁶⁵	Bernhard, Cella (1998)
		Select sites with adequate resources	2	May limit the number of participants recruited Sites with adequate resources may not necessarily be sites with best compliance record.	Hurny (1992)
	Provide PRO-specific guidance for the research team	General administration guidance aiming to standardise administration of PROs	27	None	Bernhard, Peterson (1998), Calvert (2004), Cella (1994), Cella (1995), Fayers (1997), Friedman (1998), Ganz (1988), Hahn (1998), Hayden (1993), Hopwood (1998), Kaasa (1998), Kaasa (1992), Land (2007), Newgard (2010), Osoba (1996), Osoba (1992), Sprangers (2002), Taphoorn (2010), Vantongelen (1989), Walker (2003), Wisniewski (2006) Bernhard, Peterson (1998)
		Flexible processes across sites (There may be local variations in who is	1	May introduce bias if procedures differ too much between recruiting sites	

Continued

Table 2 Continued

Category						Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks		
	Protocol guidance ^{60 61 63}	responsible for PRO data collection at different sites; therefore, procedures should be flexible to accommodate such differences.)				
		Importance of complete data must be stressed in PRO administration guidance	1	None		Fayers (1997)
		Instructions to give to participants must be specified in PRO administration guidance	1	None		Wisniewski (2006)
		Procedures for missed assessments must be specified in PRO administration guidance	1	None		Calvert (2004)
		Staff roles must be specified in PRO administration guidance	3	None		Poy (1993), Young de Haes (1999)
		Procedures for handling special situations must be specified in PRO administration guidance	5	Not all difficult situations can be predicted in advance		Hahn (1998), Hopwood (1998), Hopwood (1996), Revicki (2005)
		Follow PRO protocol guidance (investigators)	2	None		Bernhard, Cella (1998), Osoba (2007)
		Develop protocol guidance for investigators (trials groups)	1	None		Osoba (1996)
		Consider costs involved with each MOA	1	None		Macefield (2013)
		Consider impact of MOA on participants' willingness to disclose information	1	The most acceptable MOA for participants may not be the most cost-effective or feasible		Hallum-Montes (2014)
MOA (ie, is the questionnaire administered in hardcopy (pen and paper), electronically, over the phone, etc)	Choice of MOA					

Continued

Table 2 Continued

Category					Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	
		Consider potential impact MOA on response rate	3	None	Hallum-Montes (2014), Cantrell (2007)
		Consider inclusion of remote participants (web-based modes may be more accommodating to remote patients than face-to-face administration)	1	None	Cantrell (2007)
		Mode preferred by sample	1	Requires additional pilot work to gauge participant preferences. Requires additional staff time and costs. Need to ensure equivalence of modes ⁶⁶	Basch (2012)
	Electronic modes of administration 'e-PROs', for example, using a computer, tablet, smart phone, etc	Allow participants to complete on their preferred electronic device	1	Requires resources to ensure compatibility of database across many types of electronic devices	Jansen (2013)
		Allows real-time compliance monitoring	1	None	Basch (2012)
		Avoid fancy layouts	1	None	Cantrell (2007)
		Avoid mandating completion of all items	2	May lead to missing item-level data if questions are of sensitive nature ⁶⁷	Cantrell (2007), Hanscom (2002)
		Present items one at a time	1	May be burdensome for participants considering cumulative time required to click between screens	Hanscom (2002)
		Avoid question presentation one at a time (to reduce response burden)	2	None	Cantrell (2007), Hallum-Montes (2014)
		Dialogue boxes for missed items	1	May be costly to develop	Wisniewski (2006)
		Electronic dictation of questions	1	May be costly to develop	Hallum-Montes (2014)
		Email PRO assessment reminders to participants	1	Requires time/resources to implement	Cantrell (2007)

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		e-PROs encouraged	1	e-PRO assessment may not be acceptable to some patient populations. May be subject to technical fault/data protection/connectivity issues	Basch (2012)
		Keep assessment simple to reduce risk of technical fault	1	None	Hjermstad (2012)
		Make all items mandatory	1	May lead to incomplete questionnaires if questions are of a sensitive nature	Cantrell (2007)
	Flexible MOA	Follow-up missed assessments with alternate mode (eg, if participant misses a face-to-face visit in which hardcopy PRO assessment was scheduled, consider calling the participant to complete PRO over the phone, or posting the questionnaire to their home address with reply-paid envelope to return completed questionnaire)	4	Requires additional staff time and resources	Bernhard, Cella (1998), Blazeby (2003)
		Interview-administered questionnaires for very sick participants	4	Requires additional staff time	Kaasa (1998), Stewart (1992), Moynihan (1998), Chassany (2002)
		Offer more than one MOA	2	May complicate data entry procedures or procedures for returning PRO data	Bernhard, Cella (1998), Gotay (2005)
		Negotiate with the site as to their preferred MOA	1	May be infeasible to implement different modes between sites—some sites may have to compromise	Simes (1998)
	Interview-administered MOA	Interview-administered MOA may improve response rates.	1	Requires additional staff time and resources	Fowler (1996)

Continued

Table 2 Continued

Category					Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	
Patient burden—minimise	Postal MOA	Complete the baseline assessment in clinic and subsequent assessments by post	1	None	Kaasa (1998)
		Include postage-paid, self-addressed envelope for easy return of completed questionnaires (when using postal MOA)	3	Requires additional staff time and postage costs. May be burdensome for participants to send questionnaires back to researchers.	Kleinpell-Nowell (2000), Poulter (1997)
			8	None	Aaronson (1990), Hahn (1998), Little, D'Agostino (2012), Macefield (2013), McMillan (2003), Revicki (2005), Walker (2003) Bell (2014)
	Minimise patient burden (general statement)	Offer assistance to participants to complete PROs (to reduce burden PRO completion)	1	Requires additional resources	Bell (2014)
		Additional assistance—childcare (offer to provide child care for participants' children so that participants can attend clinic visits in which PRO assessments are scheduled)	1	Requires additional resources	Bell (2014)
		Additional assistance—travel (offer to arrange or fund travel of participants to the clinic for scheduled PRO assessments)	1	May be difficult to engage participants away from the clinic	Little, Cohen (2012)
	Content	Avoid the need for a clinic visit where possible	1	Requires additional staff time and resources	Sprague (2003)
		Offer assistance to complete questionnaire if needed	1	None	Young, de Haes (1999)
		Clear/simple content and instructions of questionnaires	1	None	Young, de Haes (1999)
		Reduce overlap in questionnaire items	3	None	Fallowfield (1998), Walker (2003), Young, de Haes (1999)
		Collect relevant PRO data only	2	None	Bernhard, Cella (1998), Little, Cohen (2012)

Continued

Table 2 Continued

Category					Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	
	Format	Avoid using multiple questionnaires	1	None	Chassany (2002)
		Avoid written (free text) answers	1	None	Friedman (1998)
		Clear/simple format	6	None	Conroy (2003), Little Cohen (2012), Kleinpell-Nowell (2000), Bernhard, Cella (1998), Revicki (2005), Sloan (2007)
		Large/clear font	1	May increase printing costs if larger font adds pages to the questionnaire booklet	Fairclough (2010)
		Professional format (eg, use study letterhead on printed questionnaires, use consistent formatting, etc)	3	None	Kleinpell-Nowell (2000), Revicki (2005), Sloan (2007)
		Single-sided printing (some reports suggest that participants are more likely to overlook the underside of questionnaires printed double-sided)	2	Environmental burden. May increase printing costs due to additional pages in the questionnaire booklet	Fairclough (2010), Revicki (2005)
		Uniform presentation format (a consistent formatting approach appears more professional and may be easier for participants to follow, potentially reducing risk of participants skipping items inadvertently or due to lack of understanding)	2	May not be possible if using more than one questionnaire	Bernhard, Peterson (1998), Hurry (1992)
	Length of assessments	Consider participant health—sicker participants will not be able to complete long PRO assessments	3	None	Moinpour (1989), Stewart (1992), Young, de Haes (1999)
		Fewer assessment time points (ie, PRO assessments that occur regularly may be overly burdensome)	10	May sacrifice important information by assessing PRO less often	Bernhard, Cella (1998), Little, Cohen (2012), Chassany (2002), Ganz (1988), Jansen (2013), Revicki (2005),

Continued

Table 2 Continued

Category						Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks		
		Fewer pages in e-PROs (eg, minimising the number of clicks between pages may reduce burden)	1	None		Fallowfield (1998), Hurny (1992), Hao (2010), Steinhauser (2006) Cantrell (2007)
		Shorter questionnaire	18	Limits the amount of information that can be assessed using PROs		Basch (2012), Basch (2014), Bell (2014), Bernhard, Cella (1998), Bernhard, Peterson (1998), Chassany (2002), Fairclough (2010), Hjermstad (2012), Hurny (1992), Moinpour (1989), Revicki (2005), Rock (2007), Sadura (1992), Siddiqui (2014), Young, de Haes (1999) Hjermstad (2012)
		Use CAT/screening questions (allows for targeted question content and fewer items, to minimise burden)	1	Requires additional set-up costs. Can be difficult to introduce a second, non-electronic MOA if using CAT as questions administered will differ between participants		
		Use validated questionnaires	1	None		Kaasa (1992)
		Questionnaire items or formatting that participants find burdensome may be addressed in response to feedback obtained during questionnaire validation process	1			
Participant education and engagement (also see table 3)	Continued participant engagement—use strategies to keep participants engaged throughout the life of the study/trial	Adapt procedures to participant cultural group—conduct background research about the cultural groups involved	2	Requires time and resources		Wilcox (2001)
	Participant incentives for participating/completing PRO questionnaires	Offer participants access to care via/after trial/study	3	Requires time and resources		Blazeby (2003), Little, Cohen (2012), Little D'Agnostino (2012)

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Selecting a PRO measure	Acceptable measures for participants	Offer participants financial incentives	13	Requires time and resources. Conflicting evidence about the effectiveness (in general population samples) ⁶⁸ and ethical issues in patient populations	Dykema (2012), Gates (2009), Jansen (2013), Kleinpell-Nowell (2000), Little, Cohen (2012), Meyers (2003), Sherman (2005)
		Offer participants non-financial incentives	8	Requires time and resources. Conflicting evidence about the effectiveness (in general population samples) ⁶⁸ and ethical issues in patient populations	Dykema (2012), Little, Cohen (2012), Sherman (2005), Hellard (2001)
		Reimburse participants for their time/costs involved in participating (factor into study budget)	3	Requires time and resources	Hellard (2001), Little, Cohen (2012), Senturia (1998)
			5	None	Chassany (2002), Jordhoy (2010), Kaasa (1992), Revicki (2005)
		Clinically relevant measures (select PRO measures that are clinically appropriate, that is, include questions about relevant issues to specific disease/treatment)	7	None	Bernhard, Cella (1998), Friedman (1998), Ganz (2007), Gheorghe (2014), Hahn (1998), Revicki (2005)
		Features to avoid in prospective PRO measures			
		Avoid overlapping content/ highly correlated items	2	None	Beitz (1996), Taphoorn (2010)
		Avoid sensitive item content (ie, participants are more likely to skip items addressing sensitive issues such as sexuality or finances; so by avoiding such items you may minimise risk of missing PRO data)	4	Participants may have different views about what constitutes sensitive data. Some key issues for particular studies are considered sensitive, for example, sexual function	Fallowfield (1998), Jansen (2013), Pijls-Johannesma (2005), Simes (1998)
	Translated (validated) questionnaires		2	Complicates trial set up and implementation, particularly when using e-PROs	Kaasa (1998), Kleinpell-Nowell (2000)

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
PROs part of trial/ larger study	Validated measures (these are likely to be more clinically relevant and acceptable to patients)		6	None	Bernhard, Cella (1998), Blazeby (2003), Fallowfield (1998), Kaasa (1992), Siddiqui (2014)
	Other	Ordering questionnaire items chronologically may speed up completion time and be easier for patients to complete	1	We strongly recommend that researchers do not change the item order of validated questionnaires. Questionnaires should be administered in the exact format as validated.	Dunn (2003)
		Strategies for measuring sensitive issues (please see Chassany 2002 for a description of various strategies)	1	None	Chassany (2002)
	Research team should commit to the PRO substudy (eg, when part of larger trial)		11	Requires time and resources	Bernhard, Cella (1998), Bernhard, Peterson (1998), Cella (1994), Cella (1995), Chassany (2002), Hayden (1993), Kiebert (1998), Moynihan (1998)
	Incorporate PROs in trial/main study design	PROs should be a mandatory/ integral part of the trial/ larger study (ie, PRO data are not an optional extra)	10	None	Aaronson (1990), Bernhard, Cella (1998), Hayden (1993), Hurny (1992), Kaasa (1992), Movsas (2004), Osoba (2007), Sadura (1992), Siddiqui (2014), Young, de Haes (1999)
		Consider logistic factors when designing PRO study	4	None	Chassany (2002), Little, D'Agostino (2012), Wisniewski (2006), Young, de Haes (1999)
	PRO content in the study protocol ^{60 61 63}	Define end points/hypotheses (ensure PRO end point is scientifically compelling)	5	None	Cella (1994), Fallowfield (2005), Little, Cohen (2012), Taphoorn (2010), Walker (2003)
		Specify how missing data will be handled	1	May not be possible to fully plan how missing data	Calvert (2004)

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		Specify the importance of PRO assessment compliance	1	will be handled prospectively	Fayers (1997)
		Include/plan PRO aspects of the study carefully	13	None	
		Specify plans for minimising missing data (such as those listed in this review) in the protocol	11	None	Bell (2014), Fayers (1997), Ganz (2007), Hahn (1998), Hao (2010), Land (2007), Moinpour (1998), Movsas (2003), Poy (1993), Revicki (2005), Sloan (2007), Walker (2003)
		Specify PRO assessment schedule	2	None	Beitz (1996), BIQSFP (2012), Calvert (2004), Fairclough (2010), Kaasa (1998), Moinpour (1998), Revicki (2005), Simes (1998), Young, de Haes (1999)
		Specify the rationale for PRO assessment (understanding why PROs are being measured and the value the information will bring to the trial is useful for all members of the trial team, and reinforces the importance of high-quality PRO data collection)	11	None	Hopwood (1996), Moinpour (1998)
					Aaronson (1990), Bell (2014), Cella (1994), Cella (1995), Conroy (2003), Fayers (1997), Hopwood (1998), Sadura (1992)
Include PROs in the SAP†	Specify potential problems with PRO analysis in SAP		2	May not be possible to predict and prepare for all potential problems with PRO analysis when developing the SAP	Taphoorn (2010), Walker (2003)
	Plans for addressing missing data in SAP		2	May not be possible to fully plan how missing data will be handled prospectively	Bell (2014), Bernhard, Peterson (1998)
	PROs in other trial/study documents		1	None	Land (2007)

Continued

Table 2 Continued

Category					Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	
QA	QA—planning ahead	Include PRO study in relevant sections of procedural documents			
		Consider logistic factors when designing PRO study	1	None	Fallowfield (2005)
		Create study databases with QA in mind (ie, consider how PRO data completion rates will be monitored using the database)	5	Requires time and resources	Bernhard, Cella (1998), Land (2007), Moinpour (1998), Wisniewski (2006)
		Manage PROs with other trial/ study end point data (ie, in a single database)	2	Data managers will require additional training for PROs—which requires additional time and resources	Bernhard, Peterson (1998), Hurny (1992)
		Describe QA procedures in protocol	3	None	Cella (1995), Gheorghe (2014), Revicki (2005)
		Specify QA procedures in a manual	2	None	Cella (1994), Cella (1995)
		Establish target PRO compliance rates (ie, quotas that must be achieved, eg, a target of 95% indicates that no more than 5% of missing PRO questionnaires will be tolerated)	6	None	Hahn (1998), Little, Cohen (2012), Little, D'Agostino (2012), McMillan (2003), Sloan (2007)
Sample (for PRO data collection)	PRO subsample (if study power permits and if the study budget or logistics limit capacity to collect PROs from all participants, consider collecting PROs from a subsample only)	PRO data from representative subsample of the trial population	2	May be difficult administratively, particularly for site staff to implement	Simes (1998)
		Do not collect PROs from patients with advanced disease	1	QOL issues are often of very important in patients with advanced disease.	Bernhard, Cella (1998)
		Allow patients/sites to opt in to the PRO study	1		Simes (1998)

Continued

Table 2 Continued

Category						Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks		
Bernhard, Cella (1998), Simes (1998)	Sample size	Recruit motivated patients only	2	May lead to selection bias if sites or participants opt-in to PRO study May also lead to impression that PRO study is of lesser importance than other study outcomes		May lead to selection bias if only motivated participants take part in PRO study
		Separate (additional) consent for PRO study	1	Requires additional time and resources		Simes (1998)
		Increase sample size to allow for attrition	7	The rate of missing data is important, regardless of whether the available data meet sample size requirements. Although increasing sample size will improve study power in the case of low PRO completion rates, the outcomes of participants with missing PRO data may differ to those with complete PRO data—which may lead to bias.		Altman (2007), Kaasa (2002), Little, D'Agostino (2012), Sherman (2005), Stewart (1992), Tang (2002), Jordhoy (2010)
Team—design/protocol development	Involve committees (to review PRO study)	Ethics review	1	None		Movsas (2003)
		PRO committee (ie, some trials groups have a dedicated PRO committee, comprised of PRO research specialists who review and provide feedback on PRO aspects of trials)	6	Requires access to a trials group with resources for a PRO committee		Hahn (1998), Osoba (1992), Osoba (2007), Revicki (2005)

Continued

Table 2 Continued

Category					
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
	Multidisciplinary team involved in design/protocol development (each party brings unique and complementary expertise and experiences to improve the design of the PRO study)	Involve a multidisciplinary team in PRO study design	6	None	Bernhard, Cella (1998), Cella (1994), Cella (1995), Kiebert (1998), Moinpour (1998)
		Involve experienced investigators in PRO study design (to offer strategies for maximising compliance, selection of informative measures and time points, and other key aspects of study design)	2	None	Little, Cohen (2012), Little, D'Agostino (2012)
		Involve nurses in PRO study design (to offer expertise about patient experiences and relevant QOL issues, clinic environment, data collection, etc)	1	None	Hayden (1993)
		Involve patients in PRO study design (to comment on the acceptability and relevance of PRO questionnaires, suitability of assessment time points in capturing desired outcomes, patient burden, strategies to educate and engage participants, and many other important aspect of study design)	3	None	Bernhard, Peterson (1998), Hurny (1992), Moynihan (1998)
		Involve PRO experts in PRO study design (to offer strategies for maximising compliance, selection of informative measures and time points, analysis and interpretation strategies and	3	None	Fallowfield (1998), Kiebert (1998), Basch (2014)

Continued

Table 2 Continued

Category					Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Design	Topic	Specific recommendation	N recommendations*	Potential drawbacks	
		other key aspects of study design)			
		Involve site coordinators in PRO study design (to offer expertise about logistics of PRO assessment, patient experiences and relevant QOL issues, data collection strategies, etc)	4	None	Bernhard, Cella (1998), Hayden (1993), Larkin (2012), Moinpour (1998), Cella (1995)
	Support the site staff	Minimise institution/staff burden (an overly burdensome PRO assessment schedule or procedure for site staff is likely to lead to high rates of missing data)	6	None	Aaronson (1990), Young, de Haes (1999)

*Some sources may have provided a recommendation more than once.

†This review only covers proxy reporting as a strategy to facilitate interpretation of missing PRO data. If considering using proxies, please consult the literature for a review of additional challenges and implementation strategies.

CAT, computer-adaptive testing; ECOG, Eastern Cooperative Oncology Group; ePRO, PROs administered electronically; MOA, mode of administration; PRO, patient-reported outcome; QA, quality assurance; QOL, quality of life; SAP, statistical analysis plan.

Table 3 Study conduct strategies to minimise the problem of missing PRO data

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Administration procedures	Approach all participants	All participants involved in the PRO study should be approached to complete scheduled PRO assessments, including those who are very ill (Site staff should not make any decisions about who is able to complete PROs as this may lead to selection bias. The decision is the participant's.)	11	None	Bernhard, Peterson (1998), Fairclough (2010), Hopwood (1998), Bakitas (2009), McMillan (2003), Revicki (2005), Young, de Haes (1999), Aaronson (1990), Moynihan (1998)
		Assistance completing PRO measures	5	None	Fayers (1997), Kaasa (2002), Revicki (2005), Young, de Haes (1999), Fairclough (2010)
		Offer assistance to participants who need it	11	Requires additional staff time	Aaronson (1990), Bernhard, Peterson (1998), Fayers (1997), Friedman (1998), Hurry (1992), Jordhoy (2010), Bakitas(2009), Macefield (2013), Repetto (2001), Young, de Haes (1999) Blazeby (2003)
	Be organised	Record levels of assistance provided	1	None	
		Nominate who should provide assistance to participants	3	Requires additional time and resources	Cella (1995), Revicki (2005), Young, de Haes (1999)
		Ensure sufficient questionnaires available for use	1	None	Moynihan (1998)
		Prepare for upcoming assessments (have questionnaires ready)	6	None	Vantongelen (1989), Cella (1995), Coates (1998), Moinpour (1989), Revicki (2005), Young, de Haes (1999)
		Prepare to handle potential problems	1	None	Revicki (2005)
	Checking	Track when PRO assessments due	5	None	Cella (1994), Cella (1995), Young, de Haes (1999)
		Checking for missed PRO items	29	None	Calvert (2004), Cella (1994), Cella (1995), Chassany

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		Checking source data (data entry; when entering questionnaire data into database)	2	None	(2002), Davies (1994), Fallowfield (1998), Fayers (1997), Fowler (1996), Friedman (1998), Ganz (1988), Hayden (1993), Hopwood (1998), Kleinpell-Nowell (2000), Kyte (2013), Moinpour (1990), Moinpour (1998), Movsas (2003), Movsas (2004), Revicki (2005), Taphoorn (2010), Wisniewski (2006), Young, de Haes (1999) Davies (1994), Poy (1993)
		Ensure patients receive questionnaires (particularly when the patients complete questionnaires outside of clinic)	1	None	Kaasa (1998)
	PRO completion cover sheet (a form on which site staff can record whether PROs were completed and if not completed, the possible reason why)	Importance of cover sheet	1	None	Moinpour (1998)
		Recording levels of assistance	6	Requires additional time and resources to collect	Fayers (1997), Fairclough (2010), Fayers (1997), Moinpour (1998), Hopwood (1998), Revicki (2005)
		Standardised reasons for missing data (possible reasons for non-completion of PROs may be listed on a cover sheet for the convenience of site staff and for ease of data collection)	39	Requires additional time and resources to collect Reasons for missing PRO data may not be easy to determine in some cases.	Fairclough (2010), Fayers (1997), Moinpour (1998), Hopwood (1998), Revicki (2005), Bell (2014), Bernhard, Cella (1998), Blazeby (2003), Calvert (2004), Curran (1998),

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
	Missed assessments	Alternative mode of administration (if participants miss a PRO assessment, contact the participant to capture the data using an alternative mode. Also see table 2 'Mode of administration')	17	Requires additional staff time and resources. Potential for bias based on setting of completion (systematic differences between modes, particularly if one mode is interview administered, and the other is completed by patient ⁶⁶)	Fairclough (2010), Fallowfield (1998), Fayers (1997), Hahn (1998), Hao (2010), Kiebert (1998), Kleinpell-Nowell (2000), Land (2007), Little, Cohen (2012), Luo (2008), Moinpour (1990), Moinpour (1998), Revicki (2005), Simes (1998), Taphoorn (2010), Walker (2003), Wisniewski (2006), Young, de Haes (1999)
		Following up missed assessments	18	Requires additional staff time and resources	Basch (2014) Calvert (2004), Cella (1995), Fairclough (2010), Fowler (1996), Hopwood (1996), Hurny (1992), Kleinpell-Nowell (2000), Land (2007), Moinpour (1990), Revicki (2005), Stewart (1992), Walker (2003), Revicki (2005)
	Specify place of PRO completion (eg, quiet spot in the clinic)		8	May be difficult to offer a quiet place to complete questionnaires in busy clinic environment	Cella (1994), Cella (1995), Conroy (2003), Fowler (1996), Hopwood (1998), Huntington (2005), Kleinpell-Nowell (2000), Movsas (2003), Movsas (2004), Sherman (2005), Sprague (2003), Sprangers (2002), Taphoorn (2010), Wisniewski (2006), Young, de Haes (1999)
	Returning questionnaires	Specify procedures for returning questionnaires	1	None	Calvert (2004), Hurny (1992), Jansen (2013), Moynihan (1998), Sadura (1992), Sherman (2005), Young, de Haes (1999) Poulter (1997)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Participant education and engagement	Time of completion	Standardise time of completion (eg, first thing when the patient arrives at the clinic)	2	None	Bernhard, Cella (1998), Fayers (1997)
		Before seeing clinician (many sources recommended PROs should be completed before the participants have their appointment with their clinician)	4	Requires advanced planning and potential negotiation with clinician to ensure PRO assessment is complete prior to the clinic appointment. Difficulties may arise if scheduled PRO assessments do not align with clinic visits.	Fayers (1997), Sprague (2003), Young, de Haes (1999), Hopwood (1998)
	Standardised methods	Adhere to PRO assessment schedule	2	None	Moinpour (1998), Poulter (1997)
		Use standard administration methods	5	None	Cella (1995), Chassany (2002), Movsas (2003), Movsas (2004), Revicki (2005)
		Standardise methods (eg, by developing written guidance)	13	Time and minimal costs involved initially	Bernhard, Gusset (1998), Cella (1995), Chassany (2002), Fayers (1997), Gheorghe (2014), Hopwood (1998), Moinpour (1998), Movsas (2003), Movsas (2004), Osoba (2007), Poy (1993), Revicki (2005), Sadura (1992)
	Thank the participant	On completion of questionnaire (face-to-face)	6	None	Calvert (2004), Kyte (2013), Meyers (2003), Sherman (2005), Steinhäuser (2006), Young, de Haes (1999)
		Thank you letters	3	Requires additional time and resources	Steinhäuser (2006), Fallowfield (1998), Poulter (1997)
	Confidentiality	Train staff	—	—	See 'Train staff' category
		Be mindful of sensitive PRO data (ensure participants understand it will be kept confidential)	2	None	Cella (1994), Sherman (2005)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Strategies for continued participant engagement		Discuss family involvement (participants may not wish to disclose certain information if they believe family members may see the data)	1	None	Sherman (2005)
		Inform participants that PRO data are kept confidential	6	None	Calvert (2004), Fallowfield (1998), Movsas (2003), Sherman (2005), Simes (1998), Young, de Haes (1999)
		Sealed envelopes (allow participants to self-seal so they are assured of the confidentiality of data)	1	Prevents site staff from being able to check for any missing items	Fallowfield (1998)
		Site staff should offer to answer participant questions	3	None	Calvert (2004), Fayers (1997), Hurny (1992)
		Awareness of culturally sensitive issues	1	None	Bernhard, Cella (1998)
		Match staff to participant cultural group (Some participants may build rapport more easily if they liaise with a coordinator from the same cultural group.)	1	May not be possible/feasible for all studies	Cella (1995)
		Build rapport with participants	4	None	Blazeby (2003), Steinhäuser (2006)
		Educate participants about PROs (importance of PROs, how PRO data are used, how to complete PROs)	5	Requires staff time and commitment—depending on the comprehensiveness of education offered	Basch (2012), Fairclough (2010), Gotay (2005), Huntington (2005), Kaasa (1998)
		Provide clear/simple instructions for completion of PRO assessments	5	None	Bernhard, Peterson (1998), Calvert (2004), Chassany (2002), Hurny (1992), Revicki (2005)
		Encourage participants to ask for questionnaire when they are due (in case site staff forget)	2	None	Fayers (1997), Hopwood (1998)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		Ensure participants understand (PRO assessment/how to complete questionnaires, etc)	8	Requires staff time,	Moinpour (1990), Moinpour (1998), Muller-Buh (2011), Poulter (1997), Revicki (2005)
		Collect information about participants at risk of dropping out and use that information to intervene, or implement intensive follow-up strategies for these participants	4	Risk of drop out may be difficult to predict in some samples.	Little, D'Agostino (2012), Senturia (1998), Sprague (2003)
		Maintain contact with participants	4	Requires staff time, resources and commitment	Hellard (2001), Kleinpell-Nowell (2000), Senturia (1998), Wisniewski (2006)
		Send participants PRO assessment reminders	16	Requires staff time, resources and commitment	Altman (1993), Basch (2012), Bell (2014), Bernhard, Cella (1994), Cella (1995), Cella (1998), Fallowfield (1998), Jansen (2013), Kleinpell-Nowell (2000), Land (2007), Revicki (2005), Sherman (2005), Sprague (2003), Wisniewski (2006)
		Provide assistance to participants when required	1	Requires staff time, resources and commitment	Fairclough (2010)
		Provide encouragement to participants when completing PROs	4	Requires staff time, resources and commitment	Basch (2012), Bernhard, Cella (1998), Little, Cohen (2012), Revicki (2005)
		Explain reason for multiple PRO assessments	4	None	Bernhard, Peterson (1998), Calvert (2004), Hurny (1992), Sprague (2003)
		Explain and remind participants of importance of PROs	11	None	Fayers (1997), Kyte (2013), Taphoorn (2010), Wilcox (2001), Calvert (2004), Cella (1995), Chassany (2002), Conroy (2003), Hellard (2001), Sherman (2005)
		Update participants on trial/ study progress	6	Requires staff time, resources and commitment	Cella (1995), Hellard (2001), Little, Cohen (2012), Sadura (1992)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
	Informed consent (ensure these aspects of PRO study are addressed)	Instruct participants to answer honestly/no right or wrong answers	1	None	Young T, de Haes (1999)
		Inform participants that assistance is available if needed	1	None	Young T, de Haes (1999)
		Explain commitment involved for the PRO study	7	None	Bernhard, Cella (1998), Blazeby (2003), Hurny (1992), Sherman (2005), Sprague (2003), Young, de Haes (1999)
		Explain PRO assessment during informed consent process	5	None	Fallowfield (1998), Fayers (1997), Hopwood (1998), Movsas (2003), Moynihan (1998)
		Explain importance of PRO assessment	14	None	Bernhard, Cella (1998), Conroy (2003), Fairclough (2010), Fayers (1997), Friedman (1998), Hurny (1992), Kleinpell-Nowell (2000), Blazeby (2003), Revicki (2005), Taphoorn (2010), Walker (2003), Young, de Haes (1999)
		Explain importance of complete PRO data	5	None	Bernhard, Peterson (1998), Little, Cohen (2012), Young T, de Haes (1999), Kleinpell-Nowell (2000), Revicki (2005)
		Explain that participation is voluntary	1	None	Sherman (2005)
		Language translations available (participants may feel more confident using an alternative language translation that the default language offered)	1	None	Young T, de Haes (1999)
		Ensure participant understands	3	None	Ganz (1988), Young, de Haes (1999)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Participant records	Recruitment method	Participants can take information sheets home.	3	None	Fayers (1997), Land (2007)
		Face-to-face recruitment	2	None	Jansen (2013)
		Follow the recruitment protocol	1	None	Senturia (1998)
		Less aggressive recruitment methods may be more effective than more assertive methods.	2	May result in reduced recruitment. Recruitment method should not be aggressive, not lax.	Hellard (2001), Kaasa (1998)
	Obtain contact details at registration	Alternate contact (a close relative or friend who you can contact in case the participant cannot be reached)	5	Some participants may not have a trusted friend/relative to nominate as alternate contact. Alternate contact person will need to provide consent to be contacted—which may be difficult to obtain and/or implement.	Kleinpell-Nowell (2000), Senturia (1998), Sherman (2005)
		Obtain complete participant contact details	1	Participant contact details may change during the course of the study; therefore, contact details should be checked regularly.	Sprague (2003)
	Specify procedures for checking and updating participant records		3	None	Cella (1995), Moinpour (1990), Senturia (1998)
	Update participant records	Check if participant is alive (It may be distressing for friends/family members if study reminder letters are posted to participants home after they have died. This situation can be avoided by contacting the participant's doctor for updates on the participant's condition.)	2	Must be handled carefully if participants' relatives are contacted, and may require formal approval if participants' GPs are contacted	Fallowfield (1998), Hopwood (1996)
		Update participant contact details	6	Requires time and resources	Kleinpell-Nowell (2000), Little, Cohen (2012), Little, D'Agostino (2012), Meyers (2003), Young, de Haes (1999)
		Record successful strategies for contacting participants (so that these strategies may be used for future study contact)	1	None	Meyers (2003)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Quality assurance	Central monitoring for PROs	Central office monitors compliance	4	Requires planning and resources to implement	Bernhard, Cella (1998), Hayden (1993), Kiebert (1998), Land (2007)
		Appoint a central PRO coordinator/QA officer	12	Requires additional resources	Bell (2014), Bernhard, Cella (1998), Cella (1994), Cella (1995), Fallowfield (1998), Hahn (1998), Hurny (1992), Land (2007), Moinpour (1990), Poy (1993), Simes (1998), Sloan (2007)
		Real-time monitoring of PRO completion (enables prompt intervention if PRO assessments are missed)	27	Requires time, commitment and resources of site and central monitoring staff. Requires input from database developers and statisticians from set-up phase. Difficult to implement for multisite trials due to delays in obtaining PRO forms from sites, and differences between patients in recruitment time	Basch (2012), Basch (2014), Bernhard, Cella (1998), Bernhard, Gusset (1998), Bernhard, Peterson (1998), Ganz (2007), Hayden (1993), Huntington (2005), Kyte (2013), Little, Cohen (2012), Movsas (2003), Poy (1993), Revicki (2005), Siddiqui (2014), Sprague (2003), Walker (2003), Wilcox (2001), Wisniewski (2006), Young, de Haes (1999), Sprague (2003)
	Communication	Central monitors should discuss participants who withdraw with site staff (this may identify potential issues with site management and potential strategies for avoiding problems in future).	1	Requires real-time compliance monitoring, which requires time, commitment and resources of central and site staff	
		Discuss the role of site staff in responding to participants' medical needs	1	None	Sherman (2005)
		Central office should send feedback reports to sites on PRO compliance and reasons for missing PRO data (this may assist sites to recognise problematic patterns in missing	14	Requires real-time compliance monitoring, which requires time and resources of central staff	Bernhard, Peterson (1998), Bernhard, Cella (1998), Land (2007), Friedman (1998), Hahn (1998), Hurny (1992), Senturia (1998), Wilcox

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		data, and to work towards rectifying such issues). Sites should send feedback to central office (problems, participant feedback, etc, which may be able to be addressed through discussion, in future protocol amendments or in future studies)	3	Time commitment	(2001), Young, de Haes (1999), Young, Maher (1999) Bernhard, Gusset (1998), Hopwood (1998)
		Importance of regular communication between research team	20	Requires time and resources	Bernhard, Peterson (1998), Calvert (2004), Cella (1994), Cella (1995), Hayden (1993), Land (2007), Moinpour (1998), Moynihan (1998), Osoba (1992), Poy (1993), Wisniewski (2006), Young, de Haes (1999)
		Regular meetings (a forum for communication between the research team)	6	Requires time and resources	Cella (1994), Land (2007), Moinpour (1989), Osoba (1996), Sprague (2003), Wisniewski (2006)
		Share strategies for successful PRO compliance	3	None	Bernhard, Peterson (1998), Calvert (2004), Kleinpell-Nowell (2000)
		Schedule when reports are due for the sites to communicate with the central office	1	None	Cella (1995)
	Reward high performing sites/staff	Document methods of success (regarding high PRO completion rates)	1	None	Stewart (1992)
		Offer financial incentives to sites for high completion rates	5	Costs involved	Little, D'Agostino (2012), Ganz (2007), Little, Cohen (2012), Aaronson (1990), Bernhard, Gusset (1998)
		Offer incentives to sites for high completion rates (type of incentive unspecified)	4	Costs involved	Basch (2012), Bernhard, Cella (1998), Cella (1995), Hurny (1992)
		Offer National Cancer Institute (NCI, USA) credit as incentive	2	Costs involved	Land (2007)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		Offer non-financial incentives	1	Costs involved	Little, D'Agostino (2012)
		Site coordinator authorship as incentive	1	Costs involved	Moinpour (1998)
		Thank you letters to site staff	1	Time and costs involved	Land (2007)
		Travel support to high performing site staff as incentive	2	Costs involved	Hahn (1998)
	Poorly performing sites	Intervene in poorly performing sites (ie, with additional training, discussion about support needed to improve completion rates, etc)	4	Requires real-time compliance monitoring, and time and resources to implement interventions	Bernhard, Gusset (1998), Hahn (1998), Hahn (1998), Land (2007)
		Introduce incentives if improvement is seen at poorly performing sites	1	Costs involved. Need to be introduced before compliance rates fall too low.	Cella (1994)
		Penalise sites for poor compliance (eg, eliminate opportunity for future recruitment/involvement in future trials)	5	May reduce morale at that site if not handled appropriately	Bernhard, Cella (1998), Hayden (1993), Land (2007), Moinpour (1998)
		Terminate recruitment at poorly performing sites	2	May reduce number of patients eligible for recruitment	Fayers (1997), Poy (1993)
	QA should be in place to promote high completion rates	–	10	Requires commitment and resources to implement	Bell (2014), Bernhard, Cella (1998), Bernhard, Peterson (1998), Cella (1995), Moinpour (1989), Moinpour (1998), Osoba (2007), Poy (1993), Revicki (2005)
	Rate site's performance and assess against benchmark compliance rates		1	Requires real-time compliance monitoring, which requires central staff time and resources	Land (2007)
	Site-level monitoring	Sites should be prepared for regulator inspections	1	Requires time and commitment of site and central staff	Poy (1993)
		Sites should also monitor their own compliance rates	1	Requires time and resources	Hahn (1998)
	Support for sites/staff	Offer ongoing training to site staff	4	Time and costs involved	Cella (1994), Cella (1995), Hahn (1998), Revicki (2005)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Site coordinator	Appoint a site coordinator—an individual at each site responsible for PRO administration for the study	Send site staff reminders (for upcoming/overdue PRO assessments)	32	Requires time and resources	Basch (2012), Bernhard, Cella (1998), Bernhard, Peterson (1998), Cella (1994), Cella (1995), Fairclough (2010), Hahn (1998), Hayden (1993), Hurny (1992), Land (2007), Moinpour (1989), Moinpour (1998), Osoba (1992), Poulter (1997), Revicki (2005), Sadura (1992), Siddiqui (2014), Simes (1998), Vantongelen (1989)
			34	Costs involved	Beitz (1996), Bernhard, Cella (1998), Bernhard, Peterson (1998), Blazeby (2003), Calvert (2004), Cella (1994), Cella (1995), Conroy (2003), Fallowfield (1998), Fayers (1997), Ganz (1988), Gotay (2005), Hahn (1998), Hayden (1993), Hopwood (1998), Hurny (1992), Kaasa (1992), Kyte (2013), Moinpour (1989), Moinpour (1990), Muller-Buh (2011), Poulter (1997), Revicki (2005), Stewart (1992), Young, de Haes (1999)
		Roving coordinator (Rural/remote centres may have too few participants to warrant appointing a dedicated site coordinator. Instead a roving coordinator may be responsible for several such sites.)	1	Costs involved May be difficult to implement if rural centres are geographically distant, and if participants have similar PRO assessment schedules	Scott (2004)
		Nominate a back-up site coordinator (If a primary site coordinator is absent, this	3	Requires additional resources to ensure back-up coordinator is adequately trained and informed about the PRO study	Calvert (2004), Fayers (1997), Revicki (2005)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
	Characteristics of site coordinator	individual will take responsibility for the trial.)			
		Committed to the study	2	None	Blazeby (2003), Larkin (2012), Moinpour (1998)
		Site staff should be accommodating/flexible	7	The flexibility of site staff is limited by their individual schedules and the resources available at the site	Senturia (1998), Sherman (2005), Sprague (2003)
		Interpersonal skills	1	Interpersonal skills cannot always be taught	Bernhard, Cella (1998)
		Languages spoken (if the site has participants from multiple language backgrounds, it may be crucial to employ a coordinator who can speak these language/s)	1	May be difficult to recruit multilingual site coordinators	Bernhard, Peterson (1998)
	Team involved in study implementation	Positive attitude	8	Difficult to train staff to have a positive attitude. Ascertaining and intervening in such problems may be difficult to implement.	Bernhard, Cella (1998), Fairclough (2010), Kaasa (1992), Larkin (2012), Revicki (2005), Scott (2004), Sherman (2005), Osoba (2007)
		Central office staff	1	May require some education about the value and importance of complete PRO data—which may require additional time and resources	
		Physicians	2	May require some education about the value and importance of complete PRO data—which may require additional time and resources	Hurny (1992), Vantongelen (1989)
		Multidisciplinary support	2	May require some education about the value and importance of complete PRO data—which may require additional time and resources	Poy (1993)
		Site coordinators	3	May require some education about the value and importance of complete PRO data—which may require additional time and resources	Larkin (2012), Hayden (1993)

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		Participants	1	May require some education about the value and importance of complete PRO data—which may require additional time and resources	Hayden (1993)
		Sponsor	1	May require some education about the value and importance of complete PRO data—which may require additional time and resources	Poy (1993)
		PRO Committee (group of PRO experts involved with a trials group who liaise with and advise trial investigators about PRO research. Committees may review PRO aspects of protocols or may be represented on trial teams ⁶⁹)	2	May require additional time and resources	Hahn (1998), Osoba (1992)
	Support the site staff	Offer support to sites/staff (eg, psychological support, bereavement counselling)	6	Requires time and resources	Wilcox (2001), Sherman (2005), Steinhauser (2006)
		Minimise institution burden	6	None	Aaronson (1990), Young, de Haes (1999)
		Offer a flexible working environment for site staff	1	Needs to be negotiated within the needs of the PRO study	Steinhauser (2006)
		Reward site staff for their work	2	Needs to be negotiated within the resources of the study	Steinhauser (2006)
Train staff	Train site staff	Training for site coordinators is needed	27	Requires time and resources	Basch (2012), Bernhard, Cella (1998), Bernhard, Gusset (1998), Bernhard, Peterson (1998), Cella (1995), Fairclough (2010), Ganz (2007), Gotay (2005), Hahn (1998), Hopwood (1998), Huntington (2005), Hurny (1992), Movsas (2003), Movsas (2004), Moynihan (1998), Osoba (1996), Poulter (1997), Poy (1993), Revicki

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		Booster/ongoing training should also be offered, particularly if the trial/study runs over many years and staff changeover is expected.	15	Requires time and resources	(2005), Sherman (2005), Vantongelen (1989), Walker (2003) Bernhard, Cella (1998), Bernhard, Peterson (1998), Cella (1994), Cella (1995), Hahn (1998), Larkin (2012), Moinpour (1998), Revicki (2005), Wilcox (2001), Wisniewski (2006), Young, de Haes (1999), Young, Maher (1999)
	Content of training for trial staff—the following issues related to PROs should be addressed:	Poorly performing sites—additional training should be offered to help improve compliance rates in future	3	Requires central monitoring to identify poorly performing sites +time/resources to implement training	Fayers (1997), Hopwood (1998), Poy (1993)
		Communication skills (particularly for site coordinators—good communication skills are essential for ensuring the PRO study is explained to participants, ensuring participants' questions are answered, and for building rapport)	5	Requires time and resources	Bernhard, Peterson (1998), Moynihan (1998), Poy (1993), Wilcox (2001)
		Data cannot be retrieved later (this point should be made at training so that staff understand the importance of adhering to PRO assessment time windows)	1	Requires time and resources	Cella (1995)
		Good clinical practice/good research practice	1	Requires time and resources	Poy (1993)
		Informed consent (PRO issues to discuss at consent stage)	2	Requires time and resources	Little, Cohen (2012), Wisniewski (2006)
		Missing PRO data/importance of compliance	6	Requires time and resources	Fairclough (2010), Little, Cohen (2012), Luo (2008), Meyer (2009), Moinpour

Continued

Table 3 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
		Purpose/importance of PRO assessments	12	Requires time and resources	(1998), Young T, de Haes (1999) Calvert (2004), Cella (1994), Cella (1995), Hahn (1998), Hopwood (1998), Little, D'Agostino (2012), Moynpour (1998), Poulter (1997), Taphoorn (2010), Walker (2003), Young, de Haes (1999), Young, Maher (1999)
	Format of training	Standardised procedures (importance of using standardised methods to administer PROs to minimise risk of bias)	8	Requires time and resources	Bernhard, Peterson (1998), Chassany (2002), Friedman (1998), Hayden (1993), Hurmy (1992), Moynpour (1989), Sadura (1992), Sloan (2007)
		Informational newsletters (as an additional training format)	1	Requires time and resources	Moynpour (1989)
		Pilot study as a training exercise in administering PROs and addressing common problems	1	Requires time, costs and resources	Cella (1994)
		Video training (format)	3	Requires time and resources	Bernhard, Cella (1998), Hayden (1993), Revicki (2005)
	Timing of training	Requisite training for site coordinators (All site coordinators should receive training about PROs before they can work on studies with PROs.)	4	Requires time and resources	Moynpour (1990), Sadura (1992), Wisniewski (2006)
		Training at the start-up presentation (which can address study-specific PRO issues as well as general PRO issues)	2	Requires time and resources	Fallowfield (1998), Fairclough (2010)
	Train clinician investigators		6	Requires time and resources	Hahn (1998), Aaronson (1990), Poy (1993), Young, de Haes (1999)

*Some sources may have provided a recommendation more than once.
GP, general practitioner; PRO, patient-reported outcome; QA, quality assurance.

Table 4 Strategies for reporting studies with missing patient-reported outcome (PRO) data to minimise the potential for biased interpretation of findings

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
Reporting—trial reports enable readers to interpret the possible impact of missing PRO data on findings	Report PRO data collection methods (these may shed light on strategies used to minimise, or potential relationships with, missing PRO data)	Mode of administration of PROs	1	None—however, level of detail must be balanced with word limit restrictions.	Revicki (2007)
		Staff training	1	None—however, level of detail must be balanced with word limit restrictions.	Revicki (2007)
		Participant training/education	1	None—however, level of detail must be balanced with word limit restrictions.	Revicki (2007)
	Study power calculation and power achieved for the PRO analysis (Has missing data led to substantial loss of power for PRO analyses?)		1	None	Revicki (2007)
	Report analysis methods used	PRO analysis methods	2	None—however, level of detail must be balanced with word limit restrictions.	Bernhard, Cella (1998), Revicki (2005)
		Assumptions of PRO analyses, including assumptions about missing PRO data	2	None—however, level of detail provided must be balanced with word limit restrictions.	Bell (2014), Revicki (2005)
		How missing PRO data was handled for the analysis	9	None	Calvert (2013), Chassany (2002), Machin (1998), Machin (1998), Noyez (2011), Revicki (2005), Staquet (1996)
		Sensitivity analyses (How has missing data impacted the findings?)	2	None—however, level of detail must be balanced with word limit restrictions.	Bell (2014), Revicki (2005)

Continued

Table 4 Continued

Category	Topic	Specific recommendation	N recommendations*	Potential drawbacks	Source/s: first author (year). Full citations are provided as Online Supplementary Appendix C
	Describe the sample	Clinical and demographic characteristics, including baseline PRO scores	5	None	Hewitt (2010), Noyez (2011), Revicki (2005)
		Compare participants with and without missing data	4	None—however, level of detail provided must be balanced with word limit restrictions.	Dumville (2006), Hewitt (2010), Sprangers (2002), Revicki (2005)
		Flow diagram (for PRO study), including rates and reasons for non-completion	1	None—however, level of detail must be balanced with word limit restrictions	Revicki (2005)
	Report missing data details	Compliance definitions (What was considered a missing response? How was PRO assessment compliance measured?)	1	None—however, level of detail must be balanced with word limit restrictions.	Lee (2000)
		Report the expected PRO completion rate (number of participants alive and on the study per time point) ⁷⁰	3	None	Bernhard (1998), Lee (2000), Revicki (2007)
		Report rates of missing PRO data	26	None	Bell (2014), Bernhard, Cella (1998), Calvert (2013), Chassany (2002), Fallowfield (2005), Flores (2004), Kaasa (2002), Lee (2000), Luo (2008), Machin (1998), Noyez (2011), Revicki (2005), Revicki (2007), Staquet (1996), Walker (2003)
		Report reasons for/type of missing PRO data	15	None—however, level of detail provided must be balanced with word limit restrictions	Bernhard, Cella (1998), Calvert (2013), Chassany (2002), Deo (2011), Fallowfield (2005), Flores (2004), Lee (2000), Macefield (2013), Machin (1998), Noyez (2011), Revicki (2007), Sprangers (2002), Staquet (1996), Walker (2003)
	Potential bias due to non-response/impact on generalisability	Authors should consider and report how missing data may have impacted the generalisability of findings.	6	None—however, level of detail must be balanced with word limit restrictions.	Bell (2013), Klee (1999), Machin (1998), Revicki (2005)

*Some sources may have provided a recommendation more than once.

communication with poorly performing sites led to reductions in rates of missing baseline PROs. Many trial groups have reported success of centralised monitoring systems for maintaining high PRO completion rates.^{29 35–37}

Staff should have access to ongoing training and written guidance, and should understand the importance of PROs.^{5 26 32 34 37–42} The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has attributed high PRO completion rates to training the trial team about the importance of avoiding missing PRO data.⁴³ Patient engagement is also crucial. Hellard *et al*⁴⁴ found that sending participants' study updates was the primary reason for high-level participant engagement and retention, and weekly study diary completion rates of 90.7% over 68 weeks. All of these recommendations require intensive resources^{45 46} and research team commitment,⁴⁷ and highlight the importance of conducting appropriate feasibility checks before activating the study. Research investigators, sponsors and funding bodies have a responsibility to ensure research funds are allocated to quality assurance of PRO studies. Training regarding the importance and efficacy of specific quality assurance strategies may be the catalyst to securing such funding.

Rouette *et al*⁴⁸ found that 86% of clinicians surveyed considered missing data important in interpreting PRO findings, and that clinicians require clear summaries and recommendations for accurate interpretation of trial results. Clear and sufficient information should be reported, so readers can meaningfully interpret the possible impact (bias) of missing PRO data on findings, which is crucial for PROs to impact patient care. This involves reporting descriptions of the study sample, including baseline PRO scores; rates and reasons for missing PRO data; analysis methods, including sensitivity analyses and analysis assumptions, handling of missing data, and discussing the potential impact of missing data on PRO findings. These reporting recommendations are also addressed in the CONSolidated Standards of Reporting Trials (CONSORT) PRO extension, underscoring their importance to transparency of reporting.⁴⁹

Systematic reviews have highlighted that methods for handling missing PRO data are often incorrectly or simply not applied,^{10 14} and the extent and handling of missing PRO data is often unreported.^{8 10 49–51} These omissions may hinder the reader from being able to interpret the impact of missing data on findings. Journal editors should enforce reporting guidance such as CONSORT-PRO⁴⁹ in order to promote and maintain a high standard of research evidence. A recent study found that 31% of reviewed RCTs failed to report PRO results despite including PRO endpoints in the trial protocol.⁵² The authors could not determine reasons why the RCTs failed to report PROs; however, high rates of missing data have discouraged investigators from publishing PRO findings previously.¹¹ This represents a waste of research resources, participants' time and limited research funding as PRO findings left

unreported cannot impact patient care.⁵³ Trial registration and publication of research protocols is a motion towards avoiding such examples of publication bias; however, further action towards improving the quality of PRO data is needed, beginning with more comprehensive training about PROs for all research staff. Thus, there is an urgent need for research teams to implement the described strategies to minimise missing PRO data and when missing data are present, to reduce its impact on the quality and dissemination of results.

Strengths

The literature on missing PRO data largely comprises statistically technical material that may be inaccessible for non-statisticians. We have summarised the problems created by missing PRO data in a format accessible to anyone involved in designing, conducting or analysing a clinical study. In response to the need for all members of the research team to assist in minimising the problem of missing data, we have provided the first systematic review to collate practical strategies to minimise the problem of missing PRO data. A comprehensive search strategy was used, developed with assistance from field experts and librarians. The review includes recommendations from a substantially large number of sources from various health disciplines. Many were discussion pieces written by highly regarded and experienced PRO experts based on strategies that their trials group or organisations have implemented, with documented improvement in PRO completion rates. This review, therefore, brings together the collective wisdom of experienced opinion leaders in the field. Further, most recommendations are generalisable across disciplines. Patterns and similarities in the recommendations extracted, as well as emerging findings of ongoing work investigating causes of missing PRO data,⁵⁴ provide evidence of their effectiveness in preventing and addressing the missing PRO data problem.

Limitations

As the majority of papers included in our systematic review were discussion or guidance pieces rather than original research reports, we were unable to apply study quality criteria used in traditional systematic reviews to the source papers. However, we did consider potential limitations of each recommendation, which is useful information for researchers considering implementing these strategies. Further, we have cited the frequency of each recommendation. High frequency may indicate widespread use and effectiveness, although we do acknowledge that some less-cited strategies may also be highly effective, and some strategies may only apply to specific disease or research contexts. Gathering empirical evidence as to the degree of effectiveness of the strategies identified in this review would be an interesting direction for future research.

Despite our efforts in extensively hand-searching reference lists and citing articles, it is possible that relevant

sources and/or recommendations were missed. We restricted our database search to MEDLINE and CINAHL databases, and excluded non-English sources. Searching of non-English language databases may have identified additional publications; however, since many themes were identified by numerous sources, we do not believe that this would significantly affect our findings.^{55 56} Coding of recommendations was a subjective process and, as with all qualitative approaches, is subject to interpretation of the analysts; however, rounds of code checking ensured the original meaning of recommendations was retained as far as possible.

This paper discusses one aspect of PRO data quality: data completeness. Many other factors contribute to high-quality PRO data, such as clinical and psychometric appropriateness of PRO measures (valid, reliable, responsive), compliance with time windows, and ensuring that patients self-complete.⁵⁷ Likewise, many factors can contribute to invalid interpretation of PRO data, including multiple hypothesis testing⁵⁷ and clinical versus statistical significance.^{58 59} Some of these issues have been addressed in the context of missing data in this review, but are independently crucial PRO assessment concerns. Readers are directed to the following sources for further guidance on PRO study design,⁵⁷ protocol development,^{60 61} analysis^{17 57} and reporting^{49 62} of PRO studies.

Implications

We recommend that all members of the research team involved in designing, collecting, analysing and reporting PRO data implement the strategies outlined in this review to minimise the problem of missing PRO data. Missing PRO data are preventable in many cases through rigorous study design and methodology. Further guidance on PRO-specific content of trial protocols is required, and is currently under development in the form of a Standard Protocol Items for Clinical Trials (SPIRIT)-PRO extension.⁶³ Significant funding, and staff and participant time is invested in PRO studies. Poorly conducted PRO studies with high rates of preventable missing data yield poor quality evidence. Funding organisations and sponsors should actively promote high-quality PRO research by mandating PRO training for research team members, and publication of PRO findings (adhering to CONSORT PRO extension where applicable) to optimise the value of PRO data and avoid research waste.^{53 63}

However, we acknowledge that in some health settings, missing PRO data are not avoidable due to deteriorating health status of the participants. We have also outlined strategies that may assist statisticians to appropriately handle unavoidable missing PRO data to minimise bias. Again, transparent and complete reporting of missing PRO data and analysis methods, as described in this review, will promote valid interpretation of PRO findings and assist investigators to make better-informed recommendations for patient care, policy and therapeutic labelling.

CONCLUSION

It is essential that all researchers involved in design, conduct, analysis and reporting of PRO data appreciate why missing data is a problem, why in many circumstances statistical methods for handling missing data are not failsafe, and how all members of the research team can assist in minimising the problem of missing PRO data, so that misunderstandings do not become a barrier to achieving the highest possible PRO completion rates. To not do so represents a great waste of research resources and valuable PRO evidence. Careful planning of PRO studies can minimise the risk and problem of missing PRO data. Ongoing quality assurance and team commitment throughout study implementation is also essential, which may be facilitated by involvement of PRO experts and sponsors. Despite the existence of missing PRO data, it is possible to make valid conclusions about the effect of disease and treatment on the patient if missing data are appropriately handled and analysed, and transparently reported.

Author affiliations

¹Central Clinical School, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia

²Psycho-oncology Co-operative Research Group, School of Psychology, University of Sydney, Sydney, New South Wales, Australia

³Department of Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, Ontario, Canada

⁴Institute of Applied Health Research, University of Birmingham, Birmingham, UK

⁵NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia

Acknowledgements The authors gratefully acknowledge the support of the librarians, Rebecca Goldsworthy and Jeremy Cullis (Faculty Liaison Librarians, Sydney Medical School, University of Sydney), and Shawn Hendriks (Clinical Outreach Librarian, Queen's University) in developing the search strategy.

Contributors RM-B, MB, MC, MRS and MTK were involved in study concept. RM-B, MB, MC and MTK were involved in study design. RM-B, MJP, MB, MC and MTK were involved in data acquisition and analysis. RM-B was involved in manuscript preparation. RM-B, MB, MC and MTK were involved in manuscript editing. RM-B, MJP, MB, MC, MRS and MTK were involved in manuscript review.

Funding RM-B is supported by Sydney Catalyst, courtesy of the Cancer Institute New South Wales. MTK is supported by the Australian Government through Cancer Australia.

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The authors have published all relevant data collected as part of this study; however, readers are invited to contact the corresponding author if further information is desired.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Cherny NI, Sullivan R, Dafni U, *et al.* A standardised, generic, validated approach to stratify the magnitude of clinical benefit that

- can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). *Ann Oncol* 2015;26:1547–73.
2. Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. FDA, 2009. <http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf> (accessed 10 Mar 2014).
 3. European Medicines Agency. Oncology Working Party. Draft Reflection Paper on the use of patient reported outcome (PRO) measures in oncology studies. EMA, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500168852.pdf (accessed 2 Sept 2014).
 4. Little RJ, D'Agostino R, Cohen ML, *et al*. The prevention and treatment of missing data in clinical trials. *N Engl J Med* 2012;367:1355–60.
 5. Bernhard J, Cella DF, Coates AS, *et al*. Missing quality of life data in cancer clinical trials: serious problems and challenges. *Stat Med* 1998;17:517–32.
 6. Staquet M, Berzon R, Osoba D, *et al*. Guidelines for reporting results of quality of life assessments in clinical trials. *Qual Life Res* 1996;5:496–502.
 7. Bernhard J, Gelber RD, Hürny C. Preface. *Stat Med* 1998;17:511–12.
 8. Bylicki O, Gan HK, Joly F, *et al*. Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. *Ann Oncol* 2015;26:231–7.
 9. Efficace F, Fayers P, Pusic A, *et al*. Quality of patient-reported outcome reporting across cancer randomized controlled trials according to the CONSORT patient-reported outcome extension: a pooled analysis of 557 trials. *Cancer* 2015;121:3335–42.
 10. Fielding S, MacLennan G, Cook JA, *et al*. A review of RCTs in four medical journals to assess the use of imputation to overcome missing data in quality of life outcomes. *Trials* 2008;9:51.
 11. Friedlander M, Mercieca-Bebber RL, King MT. Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learned. *Ann Oncol* 2016;27(Suppl 1):i66–71.
 12. Fairclough DL, Peterson HF, Cella D, *et al*. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. *Stat Med* 1998;17:781–96.
 13. Fairclough DL, Peterson HF, Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? *Stat Med* 1998;17:667–77.
 14. Bell ML, Fiero M, Horton NJ, *et al*. Handling missing data in RCTs: a review of the top medical journals. *BMC Med Res Methodol* 2014;14:118.
 15. Rubin DB. Inference and missing data. *Biometrika* 1976;63:581–92.
 16. Tabachnick B, Fidell L. *Using multivariate statistics*. Needham Heights, MA: Allyn & Bacon, 2012.
 17. Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. *Stat Methods Med Res* 2014;23:440–59.
 18. Curran D, Bacchi M, Schmitz SFH, *et al*. Identifying the types of missingness in quality of life data from clinical trials. *Stat Med* 1998;17:739–56.
 19. Dong Y, Peng CY. Principled missing data methods for researchers. *Springerplus* 2013;2:222.
 20. Curran D, Molenberghs G, Fayers PM, *et al*. Incomplete quality of life data in randomized trials: missing forms. *Stat Med* 1998;17:697–709.
 21. Fielding S, Fayers PM, Ramsay CR. Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches. *Health Qual Life Outcomes* 2009;7:57.
 22. Moher D, Liberati A, Tetzlaff J, *et al*. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med* 2009;6:e1000097.
 23. Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. *BMC Med Res Methodol* 2009;9:59.
 24. Gale NK, Heath G, Cameron E, *et al*. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol* 2013;13:117.
 25. Land SR, Ritter MW, Costantino JP, *et al*. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. *J Clin Oncol* 2007;25:5113–20.
 26. Cella DF, Lloyd SR. Data collection strategies for patient-reported information. *Qual Manag Health Care* 1994;2:28–35.
 27. Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. *Lung Cancer* 2005;48:365–77.
 28. Little RJ, Cohen ML, Dickersin K, *et al*. The design and conduct of clinical trials to limit missing data. *Stat Med* 2012;31:3433–43.
 29. Walker M, Brown J, Brown K, *et al*. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. *J Neurooncol* 2003;63:179–86.
 30. Taphoorn MJ, Sizoo EM, Bottomley A. Review on quality of life issues in patients with primary brain tumors. *Oncologist* 2010;15:618–26.
 31. Aaronson NK. Quality of life research in cancer clinical trials: a need for common rules and language. *Oncology (Williston Park, NY)* 1990;4:59–66.
 32. Young T, de Haes D, Curran D, *et al*. *Guidelines for assessing Quality of Life in EORTC clinical trials*. Brussels: EORTC QOL Group, 2002.
 33. Fallowfield L. Compliance issues in quality of life assessment: experiences of two Cancer Research Campaign sponsored groups. *Stat Med* 1998;17:541–6.
 34. Larkin ME, Lorenzi GM, Bayless M, *et al*. Evolution of the study coordinator role: the 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). *Clin Trials* 2012;9:418–25.
 35. Bernhard J, Gusset H, Hürny C. Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research. *Stat Med* 1998;17:633–9.
 36. Ganz PA, Day R, Costantino J. Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. *Stat Med* 1998;17:613–22.
 37. Wisniewski SR, Leon AC, Otto MW, *et al*. Prevention of missing data in clinical research studies. *Biol Psychiatry* 2006;59:997–1000.
 38. Bernhard J, Peterson HF, Coates AS, *et al*. Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. *Stat Med* 1998;17:587–601.
 39. Hahn EA, Webster KA, Cella D, *et al*. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. *Stat Med* 1998;17:547–59.
 40. Cella DF. Methods and problems in measuring quality of life. *Support Care Cancer* 1995;3:11–22.
 41. Wilcox S, Shumaker SA, Bowen DJ, *et al*. Promoting adherence and retention to clinical trials in special populations: a women's health initiative workshop. *Control Clin Trials* 2001;22:279–89.
 42. Young T, Maher J. Collecting quality of life data in EORTC clinical trials—what happens in practice? *Psychooncology* 1999;8:260–3.
 43. Osoba D, Dancy J, Zee B, *et al*. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. *J Natl Cancer Inst* 1996; Monographs 2: 107–111.
 44. Hellard ME, Sinclair MI, Forbes AB, *et al*. Methods used to maintain a high level of participant involvement in a clinical trial. *J Epidemiol Community Health* 2001;55:348–51.
 45. Revicki D, Fairclough D. Preventing missing data. In: Fayers P, Hays R, eds. *Assessing quality of life in clinical trials: analysis and interpretation*. 2nd edn. Oxford University Press, 2005:209–222.
 46. Scott RB, Farmer E, Smiton A, *et al*. Methodology of neuropsychological research in multicentre randomized clinical trials: a model derived from the International Subarachnoid Aneurysm Trial. *Clin Trials* 2004;1:31–9.
 47. Hayden KA, Moinpour CM, Metch B, *et al*. Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. *Oncol Nurs Forum* 1993;20:1415–19.
 48. Rouette J, Blazeby J, King M, *et al*. Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives. *Qual Life Res* 2015;24:1317–25.
 49. Calvert M, Blazeby J, Altman DG, *et al*. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA* 2013;309:814–22.
 50. Brundage M, Bass B, Davidson J, *et al*. Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. *Qual Life Res* 2011;20:653–64.
 51. Mercieca-Bebber RL, Perreca A, King M, *et al*. Patient-reported outcomes in head and neck and thyroid cancer randomised controlled trials: a systematic review of completeness of reporting and impact on interpretation. *Eur J Cancer* 2016;56:144–61.
 52. Schandelmaier S, Conen K, von Elm E, *et al*. Planning and reporting of quality-of-life outcomes in cancer trials. *Ann Oncol* 2015;26:1966–73.
 53. Glasziou P, Altman DG, Bossuyt P, *et al*. Reducing waste from incomplete or unusable reports of biomedical research. *Lancet* 2014;383:267–76.

54. Palmer M, Mercieca-Bebber R, King M, *et al.* A framework for classifying root causes of missing data for patient reported outcomes in prospective studies. *Qual Life Res* 2015;24:a2016.
55. Juni P, Holenstein F, Sterne J, *et al.* Direction and impact of language bias in meta-analyses of controlled trials: empirical study. *Int J Epidemiol* 2002;31:115–23.
56. Moher D, Pham B, Klassen TP, *et al.* What contributions do languages other than English make on the results of meta-analyses? *J Clin Epidemiol* 2000;53:964–72.
57. Fairclough D. *Design and analysis of quality of life studies in clinical trials*. New York: Chapman & Hall, 2010.
58. King MT. A point of minimal important difference (MID): a critique of terminology and methods. *Expert Rev Pharmacoecon Outcomes Res* 2011;11:171–84.
59. Wyrwich KW, Nienaber NA, Tierney WM, *et al.* Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. *Med Care* 1999;37:469–78.
60. Calvert M, Kyte D, Duffy H, *et al.* Patient reported outcome (PRO) assessment in clinical trials: a systematic review of guidance for trial protocol writers. *PLoS ONE* 2014;9:e110216.
61. Kyte D, Duffy H, Fletcher B, *et al.* Systematic evaluation of the patient reported outcome (PRO) content of clinical trial protocols. *PLoS ONE* 2014;9:e110229.
62. Brundage M, Blazeby J, Revicki D, *et al.* Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards. *Qual Life Res* 2013;22:1161–75.
63. Calvert M, Kyte D, von Hildebrand M, *et al.* Putting patients at the heart of health-care research. *Lancet* 2015;385:1073–4.
64. Tang ST, McCorkle R. Use of family proxies in quality of life research for cancer patients at the end of life: a literature review. *Cancer Invest* 2002;20:1086–104.
65. Gheorghe A, Roberts T, Hemming K, *et al.* Evaluating the generalisability of trial results: introducing a centre- and trial-level generalisability index. *Pharmacoeconomics* 2015;33:1195–214.
66. Rutherford C, Costa D, Mercieca-Bebber R, *et al.* Mode of administration does not cause bias in patient-reported outcome results: a meta-analysis. *Qual Life Res* 2015;3:3.
67. Cantrell MA, Lupinacci P. Methodological issues in online data collection. *J Adv Nurs* 2007;60:544–9.
68. Edwards P, Roberts I, Clarke M, *et al.* Methods to increase response rates to postal questionnaires. *Cochrane Database Syst Rev* 2007; (2):MR000008.
69. Osoba D, Bezjak A, Brundage M, *et al.* Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. *Value Health* 2007;10 (Suppl 2):S138–45.
70. Osoba D, Bezjak A, Brundage M, *et al.* Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. *Eur J Cancer* 2005;41:280–7.